Clinical trials: Dengue
Dengue, Dengue Hemorrhagic Fever
Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America
Primary objectives: To describe the immune response to each dengue serotype before and after each vaccination with sanofi pasteur's CYD dengue vaccine.
- Conditions
- Dengue, Dengue Hemorrhagic Fever, Dengue Virus, Dengue Fever
- Trial name
- NCT00993447
- Testing
- CYD Dengue Vaccine, Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis
- Where
- 4 sites in Colombia, Honduras and 2 more
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Advanced Melanoma
Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With Melanoma
The purpose of this arm of the study is to find the best way to give patients this investigational product and determine if it can treat advanced melanoma by stimulating the immune system.
- Trial name
- NCT03989895
- Testing
- Dengue Virus-1 #45AZ5 (PV-001-DV)
- Volunteers
- 10 people
- Sponsor
- PrimeVax Immuno-Oncology Inc.
Healthy Volunteers
Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine
The purpose of this study is to investigate the immunogenicity and safety of the concomitant administration of TDV (subcutaneous [SC] injection) and of hepatitis A virus (HAV) vaccine (intramuscular [IM] injection) in healthy…
- Trial name
- NCT03525119
- Testing
- TDV, HAV Vaccine
- Where
- 10 sites in United Kingdom
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue
Study to Examine the Effects of Oral Fenretinide
This randomized, placebo controlled single center study examines the extent to which 600 mg/m2/day of orally administered ISLA101 (fenretinide), given prophylactically or therapeutically, may reduce or eliminate signs and…
- Trial name
- PROTECT (NCT06528457)
- Testing
- ISLA101, Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Island Pharmaceuticals
Zika Virus Infection
Safety and Immunogenicity of BBV121
To evaluate the safety, tolerability, and immunogenicity of two-doses of three-sequentially escalating cohort (2.5 µg, 5 µg and 10 µg) of BBV121 (purified inactivated adsorbed Zika virus vaccine) compared with Placebo (Alum).
- Trial name
- Zika (NCT04478656)
- Testing
- BBV121
- Where
- India
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
Randomised Clinical Trial, Double Blind
Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy Adults
This is a Phase 1, randomized, double-blind, placebo-controlled, dose escalation study. Forty-two flavivirus-naïve adults will be enrolled and will receive 3 administrations of VLPDEN-02 or control at days 0, 28, and 56.
- Conditions
- Randomised Clinical Trial, Double Blind, Dengue, Challenge Test
- Trial name
- NCT07831473
- Testing
- VLPDEN-02 1.0 µg (0.25 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 10 µg (2.5 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 100 µg (25 µg of each VLP) + ALFQ adjuvant
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- VLP Therapeutics
Dengue Fever
Surveillance of Suspected Dengue Cases for Access to Care for Subjects Identified as Seronegative or Undetermined Before Receiving CYD Dengue Vaccine in Previous Clinical Studies in Colombia
The primary objective of the study is to identify any suspected dengue case in subjects that received at least one dose of the CYD dengue vaccine who were classified as seronegative or undetermined at baseline (according to…
- Trial name
- CYD00082 (NCT04113330)
- Where
- Colombia
- Volunteers
- 918 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Healthy
A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers
A Phase 1 study to compare the safety, tolerability and immunogenicity of different dose schedules of subcutaneously (SC) administered dengue vaccine in healthy adults and to compare the immunogenicity of different dose schedules…
- Trial name
- NCT01542632
- Testing
- Takeda's Tetravalent Dengue Vaccine Candidate (TDV), TDV New Formulation
- Where
- 3 sites in United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue Fever, Dengue Hemorrhagic Fever
Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults
The aim of the study was to evaluate the safety and immunogenicity of the Dengue vaccine in a population of special interest, such as HIV-positive adults previously exposed to dengue.
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Human Immunodeficiency Virus
- Trial name
- NCT02741128
- Testing
- CYD Dengue Vaccine
- Where
- 4 sites in Brazil
- Volunteers
- 133 people
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever, Dengue Hemorrhagic Fever
Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine
The aim of this study is to evaluate the safety profile of Dengvaxia® when used in the real-world immunization setting Primary Objective: To measure the incidence of selected adverse events (AEs) and serious AEs (SAEs) occurring…
- Trial name
- NCT02948933
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Prevention of Dengue Fever
A Phase 1 Safety Study of Dengusiil in Healthy Adults
This is a Phase 1 study to assess safety and tolerability of a single subcutaneous dose of Dengusiil in healthy adults of 18 to 45 years of age.
- Trial name
- NCT04035278
- Testing
- Dengusiil
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Dengue Fever, Dengue Hemorrhagic Fever
A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines
The purpose of this study is to investigate the potential for co-administration of the first dose of CYD Dengue vaccine with childhood vaccination.
- Trial name
- NCT01064141
- Testing
- Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus, OKAVAX®:Attenuated live varicella-zoster virus and AVAXIM® 80U: Hepatitis A virus Vaccines, Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and Childhood vaccines
- Where
- Philippines
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Sanofi
Dengue Fever, Dengue Hemorrhagic Fever
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule
The aim of the study was to assess and describe the booster effect of a tetravalent CYD dengue vaccine dose administered about 5 years or more after the completion of a 3-dose vaccination schedule in Singapore.
- Trial name
- NCT02824198
- Testing
- CYD Dengue Vaccine (5 dose formulation)
- Where
- 3 sites in Singapore
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever
Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue
The purpose of this study is to investigate lot-to-lot consistency in terms of equivalence of the immune responses induced by 3 consecutive TDV lots in healthy participants aged 18 to 60 years in non-endemic country(ies) for…
- Trial name
- NCT03423173
- Testing
- TAK-003
- Where
- 14 sites in United States
- Volunteers
- 923 people, healthy volunteers welcome
- Sponsor
- Takeda
Infectious Diseases
Sensitivity Study of Diagnostic for Early Detection of Dengue Infection
This study is a multi-site trial assessing the sensitivity of DENV Detect™ NS1 ELISA versus standard reference tests (e.g. PCR or viral culture) for dengue diagnosis in the US and internationally.
- Trial name
- NCT02059122
- Where
- 5 sites in Argentina, Barbados and 3 more
- Volunteers
- 911 people
- Sponsor
- InBios International, Inc.
Dengue, Dengue Fever
Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
The purpose of this study was to conduct a passive surveillance of hospitalized dengue cases in participants who participated in study CYD23 (NCT00842530).
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever
- Trial name
- NCT01983553
- Where
- Thailand
- Volunteers
- 3,203 people
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Infectious Diseases
Specificity Study of Diagnostic for Early Detection of Dengue Infection
This study assesses the specificity of DENV Detect™ NS1 ELISA versus standard reference tests (e.g. PCR or viral culture) for dengue diagnosis in the US.
- Trial name
- NCT02107677
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- InBios International, Inc.
Healthy
Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years
The purpose of this study is to assess the safety of Takeda's tetravalent dengue vaccine (TDV) (previously DENVax) administered subcutaneously in healthy adults and children.
- Trial name
- NCT01511250
- Testing
- TDV
- Where
- 8 sites in Colombia, Puerto Rico and 2 more
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue Fever
A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers
Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever.
- Trial name
- NCT06665035
- Testing
- TDV
- Where
- 4 sites in Colombia, Thailand
- Volunteers
- 212 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue, Dengue Hemorrhagic Fever
Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers
The aim of the study was to assess whether the second CYD dengue vaccination could be administered concomitantly with the booster vaccination of a pediatric combination vaccine (Pentaxim™) during the same day visit but in 2…
- Trial name
- NCT01411241
- Testing
- Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus, DTaP IPV//Hib vaccine, Measles, mumps, and rubella vaccine
- Where
- 4 sites in Mexico
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company